Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo

　　1.What It Actually Is

　　Dasatinib(Sprycel)is a second-generation oral small-molecule tyrosine kinase inhibitor(TKI),not a traditional chemotherapeutic.

　　Key targets:

　　BCR-ABL1 fusion kinase(binds both active and inactive conformations);

　　SRC-family kinases(SRC,LYN,YES);

　　selected receptor kinases such as c-KIT and PDGFRβ.

　　In CML,the Philadelphia chromosome produces BCR-ABL1,driving constant proliferation.Dasatinib shuts down that signal at the kinase level.

　　2.How It Differs From Chemotherapy

　　Cytotoxic chemo hits all rapidly dividing cells—tumor,bone marrow,hair follicles,gut mucosa—causing hair loss,severe nausea,and deep myelosuppression.

　　Dasatinib selectively inhibits a defined abnormal kinase.It spares normal cells more,but:

　　Targeted does not mean nontoxic.Myelosuppression,fluid retention,bleeding,and cardiopulmonary risks still exist.

　　3.Where It Is Used

　　Adult settings:

　　newly diagnosed Ph+CML,chronic phase;

　　imatinib-resistant or intolerant Ph+CML—chronic,accelerated,or blast phase;

　　Ph+ALL with prior resistance/intolerance.

　　Pediatric settings(where the label allows,age≥1):

　　Ph+CML chronic phase;

　　newly diagnosed Ph+ALL with chemotherapy.

　　Exact population and dosing follow the current local label.

　　4.Practical Dosing Snapshot

　　Oral,once daily(advanced-phase scenarios may differ);

　　with or without food,but take at a consistent time;

　　swallow whole—do not crush or split;

　　reference start:100 mg daily for chronic-phase CML;140 mg daily for advanced CML or Ph+ALL,adjusted by label and tolerance.

　　5.Adverse Events to Watch

　　Hematologic:

　　neutropenia,thrombocytopenia,anemia;

　　bleeding from bruising to severe GI or CNS hemorrhage.

　　Non-hematologic(dasatinib-specific):

　　pleural effusion​—can be bilateral,needs imaging;

　　pulmonary arterial hypertension(PAH)​—discontinue if confirmed;

　　pericardial effusion,ascites,edema;

　　diarrhea,headache,rash,musculoskeletal pain,fatigue;

　　QT prolongation,hepatotoxicity.

　　6.Long-Term Monitoring

　　CML is managed like a chronic disease:

　　CBC​regularly;

　　BCR-ABL1 qPCR​to track molecular response depth(MMR,MR4.5)and detect relapse early;

　　liver function and chemistry;

　　ECG(high-risk)and echocardiogram when indicated;

　　chest imaging if cough,dyspnea,or chest tightness appears;

　　PAH screening for new exertional breathlessness or lower-limb edema.

　　7.Drug Interactions

　　Dasatinib is a CYP3A4 substrate:

　　strong CYP3A4 inhibitors→higher exposure,watch toxicity;

　　strong inducers→lower exposure,reduced efficacy;

　　avoid chronic PPI/H2-blocker use;separate antacids by≥2 hours;

　　no grapefruit juice.

　　8.One-Line Read

　　Dasatinib is an oral targeted therapy that switches off BCR-ABL signaling—not chemo—but it demands disciplined,specialist-led monitoring.